Membrane-interactive lipids as experimental anticancer drugs.
作者信息
Berdel W E
出版信息
Br J Cancer. 1991 Aug;64(2):208-11. doi: 10.1038/bjc.1991.277.
Abstract
摘要
相似文献
1
Membrane-interactive lipids as experimental anticancer drugs.
Br J Cancer. 1991 Aug;64(2):208-11. doi: 10.1038/bjc.1991.277.
2
Phospholipid antitumor agents.
Med Res Rev. 1995 May;15(3):157-223. doi: 10.1002/med.2610150302.
3
Ether lipids and derivatives as investigational anticancer drugs. A brief review.
Onkologie. 1990 Aug;13(4):245-50. doi: 10.1159/000216771.
4
Ether lipids in the therapy of cancer.
Prog Biochem Pharmacol. 1988;22:118-31.
5
Advances in either phospholipids treatment of cancer.
Crit Rev Oncol Hematol. 1995 Mar;18(3):155-78. doi: 10.1016/1040-8428(94)00118-d.
6
NMR spectral analysis of cytotoxic ether lipids.
J Lipid Res. 1992 Apr;33(4):605-9.
7
Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy.
Pharmacol Ther. 2016 Sep;165:114-31. doi: 10.1016/j.pharmthera.2016.06.003. Epub 2016 Jun 8.
8
Edelfosine, apoptosis, MDR and Na+/H+ exchanger: induction mechanisms and treatment implications.
Apoptosis. 2000 Feb;5(1):87-9. doi: 10.1023/a:1009645927931.
9
Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
Prog Clin Biol Res. 1990;333:1-18; discussion 19-20.
10
Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.
Cancer Treat Rev. 2007 Apr;33(2):191-202. doi: 10.1016/j.ctrv.2006.12.001. Epub 2007 Feb 6.
引用本文的文献
1
Impact of targeting the platelet-activating factor and its receptor in cancer treatment.
Mil Med Res. 2025 Mar 4;12(1):10. doi: 10.1186/s40779-025-00597-0.
2
Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe.
Cancers (Basel). 2022 Mar 3;14(5):1308. doi: 10.3390/cancers14051308.
3
Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells.
Oncotarget. 2017 Dec 20;9(5):5797-5810. doi: 10.18632/oncotarget.23537. eCollection 2018 Jan 19.
4
Evaluation of in vitro and in vivo anti-inflammatory activity of biologically active phospholipids with anti-neoplastic potential in porcine model.
BMC Complement Altern Med. 2014 Sep 19;14:339. doi: 10.1186/1472-6882-14-339.
5
Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.
Antimicrob Agents Chemother. 2003 Aug;47(8):2397-403. doi: 10.1128/AAC.47.8.2397-2403.2003.
6
MDR1 causes resistance to the antitumour drug miltefosine.
Br J Cancer. 2001 May 18;84(10):1405-11. doi: 10.1054/bjoc.2001.1776.
7
The ether lipid ET-18-OCH3 increases cytosolic Ca2+ concentrations in Madin Darby canine kidney cells.
Br J Pharmacol. 1999 Jul;127(6):1502-10. doi: 10.1038/sj.bjp.0702691.
8
New drugs for BNCT: an experimental approach.
Strahlenther Onkol. 1999 Jun;175 Suppl 2:118-20. doi: 10.1007/BF03038909.
9
Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography.
Lipids. 1999 May;34(5):511-6. doi: 10.1007/s11745-999-0392-6.
10
Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).
Br J Cancer. 1997;76(7):862-9. doi: 10.1038/bjc.1997.476.
本文引用的文献
1
The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma.
Eur J Cancer (1965). 1980 Sep;16(9):1199-204. doi: 10.1016/0014-2964(80)90179-6.
2
Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids.
Cancer Res. 1981 Aug;41(8):3211-6.
3
Destruction of human solid tumors by alkyl lysophospholipids.
J Natl Cancer Inst. 1980 Jun;64(6):1301-6. doi: 10.1093/jnci/64.6.1301.
4
5
Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine.
J Natl Cancer Inst. 1984 Jan;72(1):53-9. doi: 10.1093/jnci/72.1.53.
6
Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin.
Cancer Res. 1983 Nov;43(11):5538-43.
7
Alkyl-lysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts.
Immunobiology. 1980 Jan;156(4-5):498-508. doi: 10.1016/S0171-2985(80)80083-0.
8
Purging murine leukemic marrow with alkyl-lysophospholipids.
Blood. 1984 Dec;64(6):1288-91.
9
Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro.
Cancer Res. 1985 Jan;45(1):351-7.
10
Clonogenicity of normal and malignant hematopoietic progenitor cells after exposure to synthetic alkyl-lymphospholipids.
Blut. 1985 Dec;51(6):393-9. doi: 10.1007/BF00320725.
Zotero 插件